Drug Profile
Research programme: prostate cancer therapy - Berg Pharma/CPDR/HJF
Latest Information Update: 24 Feb 2023
Price :
$50
*
At a glance
- Originator Berg Pharma; Henry M. Jackson Foundation for the Advancement of Military Medicine; Uniformed Services University of the Health Sciences
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Prostate-cancer in USA
- 09 Aug 2013 Early research in Prostate cancer in USA (unspecified route)